米氮平与西酞普兰治疗精神分裂症后抑郁的对照研究  

Comparative study of mirtazapine and citalopram in the treatment of patients with post-schizophrenic depression

作　　者：葛红敏[1] 陈征[1] 陆永艳[1] 

机构地区：[1]天津市安定医院,300222

出　　处：《精神医学杂志》2011年第5期339-341,共3页Journal of Psychiatry

摘　　要：目的比较米氮平与西酞普兰治疗精神分裂症后抑郁的疗效和安全性。方法把69例符合入组条件的精神分裂症后抑郁患者随机分为米氮平组和西酞普兰组,分别给予米氮平和西酞普兰系统治疗,共6周。应用汉密尔顿抑郁量表(HAMD)、简明精神病量表(BPRS)及副反应量表(TESS)于治疗前和治疗2、4、6周末分别评定疗效和不良反应。结果米氮平组和西酞普兰组患者治疗有效率分别为91.67%和87.88%,两者差异无显著性意义(P>0.05)。两组治疗后HAMD和BPRS评分均较治疗前显著下降(P<0.01),在各期中HAMD、BPRS评分两组间比较无显著差异(P>0.05)。两组常见的副作用为嗜睡、口干、恶心、头痛、便秘、体重增加等,程度轻微。结论米氮平与西酞普兰治疗精神分裂症后抑郁疗效相当,不良反应轻微。Objective To compare the clinical efficacy and safety of mirtazapine and citalopram in the treatment of patients with post-schizophrenic depression （PSD） . Methods A total of 69 patients with post-schizophrenic depression were randomly divided into mirtazapine group and citalopram group treated with mirtazapine and citalopram respectively for 6 weeks. They were measured with Hamilton Depressive Scale （ HAMD）, Brief Psychiatric Rating Scale （BPRS） and Treatment Emergent Symptom Scale （TESS） at the baseline and the 2nd, 4th, 6th weekend after treatment. Results At the end of the 6th week, there was no significant aifferences in effective rate between mirtazapine group and citalopram group （91.67% vs. 87.88%, P 〉0.05）. At the end of treatment, total scores of HAMD and BPRS in two groups both decreased significantly when compared with those at baseline （ P 〈 0.01 ）. There were no significant differences in scores of HAMD and BPRS between the two groups at each interview-point （P 〉 0.05 ）. Adverse reactions in both groups were mild and the common side effects included sleepiness, dry mouth, nausea, headache, constipation, weight gain and so on. Conclusion Mirtazapine and citalopram have equivalent efficiency and safety in the treatment of patients with post-schizophrenic depression.

关 键 词：精神分裂症后抑郁 西酞普兰 米氮平 

分 类 号：R749.3[医药卫生—神经病学与精神病学]